

# A Role for the Vacuolating Cytotoxin, VacA, in Colonization and *Helicobacter pylori*-Induced Metaplasia in the Stomach

Jody A. Winter,<sup>1,a</sup> Darren P. Letley,<sup>1,a</sup> Katherine W. Cook,<sup>1</sup> Joanne L. Rhead,<sup>1</sup> Abed A. M. Zaitoun,<sup>2</sup> Richard J. M. Ingram,<sup>1</sup> Karin R. Amilon,<sup>1</sup> Nicola J. Croxall,<sup>1</sup> Phillip V. Kaye,<sup>2</sup> Karen Robinson,<sup>1,b</sup> and John C. Atherton<sup>1,b</sup>

<sup>1</sup>Nottingham Digestive Diseases Biomedical Research Unit, School of Medicine, University of Nottingham, and <sup>2</sup>Department of Pathology, Nottingham University Hospitals NHS Trust, Queen's Medical Centre Campus, United Kingdom

**Carriage of *Helicobacter pylori* strains producing more active (s1/i1) forms of VacA is strongly associated with gastric adenocarcinoma. To our knowledge, we are the first to determine effects of different polymorphic forms of VacA on inflammation and metaplasia in the mouse stomach. Bacteria producing the less active s2/i2 form of VacA colonized mice more efficiently than mutants null for VacA or producing more active forms of it, providing the first evidence of a positive role for the minimally active s2/i2 toxin. Strains producing more active toxin forms induced more severe and extensive metaplasia and inflammation in the mouse stomach than strains producing weakly active (s2/i2) toxin. We also examined the association in humans, controlling for *cagPAI* status. In human gastric biopsy specimens, the *vacA* i1 allele was strongly associated with precancerous intestinal metaplasia, with almost complete absence of intestinal metaplasia in subjects infected with i2-type strains, even in a *vacA* s1, *cagA*<sup>+</sup> background.**

**Keywords.** gastric cancer; pathogenesis; SPEM; *Helicobacter pylori*; virulence; colonization.

*Helicobacter pylori* is a gram-negative microaerophilic bacterium that infects about half the world's population and persists lifelong if untreated. Colonization of the human gastric mucosa with *H. pylori* stimulates a chronic inflammatory response with an associated lifetime risk of 10%–20% for peptic ulceration [1] and approximately 1% for gastric adenocarcinoma [2]. The risk of disease in an infected individual is determined by a combination of host factors, including genetic polymorphisms [3], environmental factors such as smoking [4], and, critically, the virulence of the

infecting strain. *H. pylori* produces multiple virulence factors, including cytotoxin-associated gene A (CagA) and the vacuolating cytotoxin (VacA), each of which is associated with a marked increase in the risk of disease development (reviewed by Kusters et al [5]).

VacA, a pore-forming toxin, was named for the vacuolation it induces in gastric epithelial cells [6] but has many other effects, including apoptosis induction in gastric epithelial cells [7] and inhibition of proliferation and IL-2 secretion by T cells [8]. CagA is translocated into gastric epithelial cells by a type IV secretion apparatus encoded within the *cag* pathogenicity island (*cagPAI*), where it induces morphological changes and proinflammatory cytokine secretion (reviewed by Noto and Peek [9]).

The *cagPAI* may be present or absent in a given *H. pylori* strain. The *vacA* gene is present in all strains but is polymorphic, having 2 alternative allelic variants at its signal (s1/s2), intermediate (i1/i2), and middle (m1/m2) regions [10, 11]. The s2 forms of VacA form pores slowly and inefficiently and induce minimal vacuolation, if any [12]. The s1 forms are more active, especially if they also have the i1 intermediate region [11]. The midregion type affects binding to some cell lines [10, 13].

Association studies in humans examining the importance of VacA in disease are hindered by a linkage

Received 22 October 2013; accepted 3 March 2014; electronically published 12 March 2014.

<sup>a</sup>J. A. W. and D. P. L. contributed equally to this work.

<sup>b</sup>K. R. and J. C. A. shared senior authorship.

Correspondence: John C. Atherton, MD, Nottingham Digestive Diseases Centre Biomedical Research Unit, School of Medicine, University of Nottingham, Nottingham NG7 2RD, UK (john.atherton@nottingham.ac.uk).

**The Journal of Infectious Diseases** 2014;210:954–63

© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

DOI: 10.1093/infdis/jiu154

between *cagA* and *vacA* genotypes [14]; most *vacA* s1 strains isolated are also *cagA*<sup>+</sup>, and most *vacA* s2 strains are *cagA*<sup>-</sup>. We reported elsewhere that the *vacA* i1 allele is the best independent predictor of gastric adenocarcinoma risk in humans, based on a multivariate analysis including *vacA* s, i, and m types and *cagA* [11]. Associations of i1-type *vacA* with peptic ulceration, gastric atrophy, and carcinoma have since been confirmed by us and others [15–17]. To date, however, there is no direct experimental evidence that these associations are causal, in part because animal models for studying pathogenesis are poor. Few *H. pylori* strains will infect mice, and the widely used SS1 strain [18] lacks *cagPAI* functionality [19, 20] and expresses nontoxicogenic s2/i2 VacA. An alternative *cagPAI*<sup>+</sup> derivative (PMSS1) [21] is also VacA s2/i2. Although many *H. pylori* strains produce VacA and CagA in humans, both are absent from other *Helicobacter* species naturally infecting animals (eg, *Helicobacter felis*). VacA and CagA have profound effects on mouse gastric epithelial cells, but murine T cells are resistant to VacA-mediated inhibition [22].

Despite these limitations, several studies have examined the role of s2/i2 VacA during infection in animal models. Early studies reported little or no difference in colonization or disease between wild-type and *vacA* null strains [23, 24], but Salama et al [25] showed that carriage of *vacA* conferred a competitive advantage over *vacA* null mutants and that presence of *vacA* facilitated colonization of mice with lower inoculating doses. More recently, Oertli et al [26] reported that *vacA* null mutants colonized mice at reduced levels while inducing stronger T-helper 1 and T-helper 17 responses. In nature, *vacA* null *H. pylori* strains are very rarely found—the gene is maintained in bacterial populations—but it is unclear why the nonvacuolating s2/i2 form is maintained so widely or what role it might play during infection.

We aimed to characterize the role of different *vacA* polymorphic forms in *H. pylori* pathogenesis. Uniquely, we determined effects of VacA polymorphisms on colonization, inflammation, and precancerous changes in mice. We also showed that the *vacA* i1 allele is associated with an increased risk of intestinal metaplasia in the gastric mucosa of infected human patients.

## MATERIALS AND METHODS

### *H. pylori* Strains

The strains used in this study were SS1<sup>s1i1</sup>, SS1<sup>s1i2</sup>, SS1<sup>s2i2</sup>, and SS1<sup>null</sup>. All strains were isogenic and constructed on the SS1 background, with *vacA* genotypes as indicated. All strains were minimally passaged. Mutants were generated by natural transformation of wild-type SS1 with plasmid pJR100 [11], containing the s1/i1-encoding region of *vacA* from strain 60190, to make SS1<sup>s1i1</sup> or with plasmid pCTB2cat [10] to make SS1<sup>s1i2</sup> and SS1<sup>s2i2</sup>. After allelic exchange by homologous recombination and chloramphenicol resistance marker rescue, the *vacA* allele in each transformant was sequenced to confirm its

genotype. The SS1<sup>s2i2</sup> strain expresses the same VacA type as wild-type SS1, in similar quantities (Figure 1) but also contains the chloramphenicol resistance cassette present in the other mutants. SS1<sup>null</sup> was produced by inserting a kanamycin resistance cassette into the *vacA* coding sequence using plasmid pCTB8::Km [27]. Because strains expressing s2i1 VacA are almost never found in human infections, an SS1<sup>s2i1</sup> strain was not constructed for this study.

### Vacuolation Assay

RK13 cells (American Type Culture Collection CCL-37) were maintained at 37°C and 5% carbon dioxide in Ham F12 medium supplemented with 2 mmol/L L-glutamine and 10% fetal bovine serum (Sigma-Aldrich). Bacterial water extracts were prepared as described elsewhere [10] and applied at 75 µg/mL to 1 × 10<sup>4</sup> cells per well in 96-well plates in the presence of 10 mmol/L ammonium chloride. After 4 hours, the extent of vacuolation was quantified with light microscopy and expressed as the mean proportion of vacuolated cells per field (≥100 cells assessed per experimental condition, 4 fields per condition, and duplicate independent experiments).

### Western Blotting


The protein concentration of each bacterial water extract was determined by means of bicinchoninic acid assay (Thermo Scientific) and adjusted to 750 µg/mL. Next, 7.5 µg of total protein per lane was separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis, and the relative VacA content of each extract was determined by Western blotting. All samples were tested on the same gel and blot. VacA was labeled by using a 1:1 mixture of rabbit polyclonal serum raised in house against VacA p33 and p55 subunits, diluted 1:10 000, and then horseradish peroxidase–conjugated goat anti-rabbit secondary antibody (Sigma), also at 1:10 000 dilution. Equal protein loading in each lane was confirmed by Coomassie staining of duplicate gels.

### Mouse Infection Study Design

All animal procedures were carried out under Home Office project license 40/3399, according to UK Home Office and institutional guidelines and with prior approval from the University of Nottingham Animal Welfare and Ethical Review Body. Groups of 6–8-week-old female C57BL/6J mice (Charles River UK) were housed in individually ventilated cages and allowed water and food ad libitum. Mice were infected with doses of 10<sup>9</sup> bacteria in 100 µL of Brucella broth (Difco Laboratories) by oral gavage on 3 alternate days. The viability of each inoculum was confirmed by quantitative culture after dosing [28], and no significant differences in viability were seen between the strains tested.

### Quantitative Culture From Mouse Stomachs and Histology

After 1, 3, or 6 weeks, mice were euthanized. Stomachs were carefully halved longitudinally along the greater and lesser



**Figure 1.** Expression levels and activities of VacA from SS1 mutant series. *A*, Water extracts (7.5  $\mu$ g total protein per lane) were Western blotted for VacA to confirm the presence or absence of toxin expression and relative quantities of toxin production. WT, wild type. *B*, RK13 cells were incubated for 4 hours in the presence of 75  $\mu$ g/mL of the water extracts shown in *A*. The extent of vacuolation was quantified with light microscopy; vacuolating activity is presented as the mean ( $\pm$  standard deviation) proportion of vacuolated cells per field of view from  $\geq 4$  fields). *C*, Representative microscopic images of vacuolation.

curvatures and rinsed in sterile phosphate-buffered saline. Half of each stomach was manually disrupted on ice in 750  $\mu$ L of Iso-Sensitest (Oxoid, Basingstoke, UK) broth/15% glycerol, serially diluted, and plated on Galaxo Selective Supplement A plates (blood agar base 2 (Oxoid) plates supplemented with 10% defibrinated horse blood, 10  $\mu$ g/mL vancomycin, 20  $\mu$ g/mL bacitracin, 4  $\mu$ g/mL amphotericin B, 2.5 IU/mL polymyxin B sulfate and 1.07  $\mu$ g/mL nalidixic acid). The other half of the stomach was formalin fixed, paraffin embedded and sectioned, then stained with hematoxylin-eosin or periodic acid-Schiff/Alcian blue. The hematoxylin-eosin-stained sections were scored for severity of inflammation and spasmodic polypeptide-expressing metaplasia (SPEM) by the same qualified histopathologist (P. V. K.) in a blinded manner. Sections were assigned scores

of 0 (absent), 1 (mild), 2 (moderate), or 3 (severe). Because inflammation and SPEM were patchy in the mouse gastric mucosa after 1–6 weeks of infection, the length of each was measured and normalized to the total length of corpus examined, to quantify the extent of inflammation and SPEM for each mouse.

#### Human Studies

We studied patients attending the Queen's Medical Centre, Nottingham, United Kingdom, between 2002 and 2012 for routine upper gastrointestinal endoscopy, usually for investigation of dyspepsia. Written informed consent was obtained from all patients, with approval of the Nottingham Research Ethics Committee 2 (08/H0408/195). Gastric biopsy specimens were collected into Iso-Sensitest broth/15% glycerol for culture and

further biopsy specimens were formalin fixed for histological examination. We examined an unselected group of patients for whom histological data were available and *H. pylori* successfully cultured. Samples from patients who had taken nonsteroidal anti-inflammatory drugs or antibiotics in the 2 weeks before endoscopy were excluded from the study. The population was 52% male with an age range of 17–82 years (median, 55 years).

A qualified histopathologist (A. A. M. Z.), who was blinded to other data, used the updated Sydney scoring system [29] to score colonization density, inflammation, activity, atrophy, and intestinal metaplasia in biopsy sections. The *H. pylori* strains cultured from biopsy specimens were typed for *vacA* by polymerase chain reaction (PCR), according to established methods [11, 30, 31]. PCR typing for presence or absence of the *cagA* gene was carried out using primers A22F (5'-TTCATGGGCGTGTGTTGATG) and A23R (5'-ATAATCTTTGAGAGTGTAGCTC) [32] alongside reference strains 60190 (*cagA*<sup>+</sup>) and Tx30a (*cagA*<sup>-</sup>). Specimens that were negative for *cagA* at PCR were confirmed serologically with use of a CagA immunoglobulin G enzyme-linked immunosorbent assay kit (Genesis Diagnostics).

### Statistical Analysis

GraphPad Prism software (version 5; GraphPad) was used for all statistical analyses. The tests used are indicated in the figure legends.

## RESULTS


### Production and Characterization of Isogenic *vacA* Mutants in the SS1 Strain Background

We engineered wild-type SS1 (SS1<sup>WT</sup>, naturally *vacA* s2/i2/m2 and unable to translocate CagA) [18, 33–35] to produce s1/i1 (SS1<sup>s1i1</sup>) or s1/i2 (SS1<sup>s1i2</sup>) *VacA*, using a chloramphenicol resistance cassette to recover transformants. To control for the possibility that this engineering adversely affected the strain, we also constructed a strain producing wild-type s2/i2 *VacA* using the same cassette (SS1<sup>s2i2</sup>). Finally, we disrupted the *vacA* gene in SS1<sup>WT</sup> to produce SS1<sup>null</sup> mutants.

SS1<sup>WT</sup>, SS1<sup>s1i1</sup>, SS1<sup>s1i2</sup>, and SS1<sup>s2i2</sup> had similar growth rates and adherence to AGS and RK13 cells (data not shown) and expressed similar quantities of *VacA* (Figure 1A). As expected, water extracts prepared from SS1<sup>s1i1</sup> caused extensive vacuolation of RK13 cells, whereas those from SS1<sup>s1i2</sup>, SS1<sup>s2i2</sup>, and SS1<sup>null</sup> caused minimal or no vacuolation (Figure 1B and 1C).

### Promotion of Gastric Colonization in Mice by Nontoxicogenic s2/i2 *VacA*


Consistent with the findings of Salama et al [25] and Oertli et al [26], in our hands SS1<sup>null</sup> was impaired for colonization in 5 independent experiments. SS1<sup>null</sup> mutant 1 was recovered from only 1 of 19 mice 3 weeks after infection, and mutant 2 was



**Figure 2.** Expression of s2/i2 *vacA* promotes *Helicobacter pylori* colonization in mice. Mice were infected with SS1 expressing s1/i1, s1/i2, or s2/i2 or null for *vacA*. After 3 weeks, gastric colonization densities were determined by quantitative culture. Data shown for each group are combined from a minimum of 4 independent experiments. Data for *vacA* null group are combined from 2 independently produced *vacA* null mutants. *A*, Proportion of mice from which *H. pylori* was successfully recovered 3 weeks after inoculation. *B*, Colonization densities in the stomachs of infected mice. SS1<sup>s1i1</sup> and SS1<sup>s1i2</sup> colonized mice to 7.4-fold and 7.3-fold lower mean densities, respectively, than SS1<sup>s2i2</sup>. Of 26 mice inoculated with SS1<sup>null</sup>, bacteria were recovered from only 4 mice after 3 weeks, and the colonization densities were highly variable. Data were analyzed by means of 1-way analysis of variance with Tukey posttest. Horizontal lines indicate mean values for each experimental group. Abbreviation: CFU, colony-forming units.

recovered from 3 of 7 (combined data from 26 mice inoculated with SS1<sup>null</sup> are shown in Figure 2). SS1<sup>s2i2</sup> colonized mice readily (93% of mice successfully infected), with gastric colonization densities similar to those we usually detect for SS1<sup>WT</sup>. Given that the null mutants had reduced colonization rates, indicating a role for *VacA*, we were surprised to find that the SS1<sup>s1i1</sup> and SS1<sup>s1i2</sup> strains were also impaired for colonization (Figure 2). Expression of type s1/i1 or s1/i2 *VacA* significantly reduced both the proportion of successful infections (24% for SS1<sup>s1i1</sup>

and 15% for SS1<sup>s1i2</sup>) and gastric colonization densities in successfully infected mice, compared with expression of s2/i2-type VacA (7.4-fold for SS1<sup>s1i1</sup> [ $P < .01$ ] and 7.3-fold for SS1<sup>s1i2</sup> [ $P = .08$ ]). This indicates that expression of nontoxicogenic s2/i2 VacA confers an advantage for *H. pylori* over s1/i2 or s1/i1 VacA.



**Figure 3.** Infection with SS1<sup>s1i1</sup> induces spasmodic polypeptide-expressing metaplasia (SPEM) and inflammation in mouse gastric mucosa. *A*, Hematoxylin-eosin (HE)-stained gastric sections from a mouse 3 weeks after dosing with SS1<sup>s1i1</sup> in Brucella broth showing inflammatory infiltrate (asterisk), loss of specialized gland cells, and marked expansion of cells with foamy cytoplasm indicative of mucinous metaplasia (arrows). *B*, Periodic acid–Schiff (PAS)/Alcian blue staining on gastric sections from SS1<sup>s1i1</sup>-dosed mice after 3 weeks of infection confirmed the replacement of specialized gland cells with mucin-containing cells (blue-staining acid mucin and purple-staining neutral mucin), consistent with SPEM [36]. *C*, Sections from a mouse dosed with Brucella broth only. *D*, SPEM was absent 3 weeks after dosing with Brucella broth. Panels *A* and *B* are representative of SPEM and inflammation scores of 3 (severe); panels *C* and *D* representative of inflammation scores of 0 (absent). Bar represents 200  $\mu$ m for all panels.

### Induction of Inflammation and SPEM by Expression of s1/i1-Type vs s2/i2-Type VacA in the SS1 Mouse Model

Gastric tissue sections from inoculated mice were stained with hematoxylin-eosin and scored for intensity of inflammation and SPEM. In the gastric mucosa after 3 weeks of infection, areas of inflammation and SPEM were visible and in some cases extensive (Figure 3) but were interspersed with patches of normal-appearing mucosa. Consistent with previous reports [36], SPEM in infected mice was characterized by the loss of specialized gland cells and expansion of metaplastic cells with abundant, “foamy” mucin-filled cytoplasm that stained purple/blue with periodic acid–Schiff/Alcian blue (Figure 3).


There were no correlations between colonization density and severity or extent of inflammation or SPEM. However, 3 weeks after inoculation, SPEM was significantly more extensive in mice given SS1<sup>s1i1</sup> than in those given SS1<sup>s2i2</sup> ( $P < .05$ ), and throughout the study there were trends to more severe and extensive gastric inflammation and SPEM in mice given SS1<sup>s1i1</sup> than in those given SS1<sup>s1i2</sup> or SS1<sup>s2i2</sup> (Figure 4), findings further confirmed in the time course studies below.

To determine whether inflammation and SPEM would rapidly resolve after an acute phase immediately after inoculation, or progress over time, we conducted time course infection studies for SS1<sup>s1i1</sup> and SS1<sup>s2i2</sup>, with histological analysis 1, 3, and 6 weeks after inoculation. Inflammation and SPEM became increasingly extensive over time, and the proportion of mice in each group with moderate to severe inflammation and SPEM also increased (Figure 5). Although this experiment was to determine time courses of individual mutants, experiments were performed concurrently, so further comparisons between mutants were possible. Mice given SS1<sup>s1i1</sup> had more severe ( $P = .07$ ) and extensive ( $P = .08$ ) SPEM than those given SS1<sup>s2i2</sup> at 1 week after dosing, but inflammation was minimal in both groups at this early time point. SS1<sup>s1i1</sup> and SS1<sup>s2i2</sup> induced similar levels of inflammation and SPEM after 3 and 6 weeks, even though SS1<sup>s1i1</sup> colonized only 1 mouse to detectable levels (SS1<sup>s2i2</sup> colonized all mice at high levels); thus, the amount of inflammation and SPEM per viable bacterium was much higher in the SS1<sup>s1i1</sup>-infected animals.

### vacA i Region Type and Risk of Intestinal Metaplasia in Humans

Given the impact of *vacA* polymorphisms on gastric histopathology in mice and the strong association between carriage of i1-type strains and gastric adenocarcinoma in human populations, we went on to examine associations of *vacA* type with intestinal metaplasia in *H. pylori*-infected patients.

*H. pylori* was successfully isolated by culture from gastric biopsy specimens taken from 85 patients. Of these, 62% of strains ( $n = 53$ ) were *vacA* s1/i1 type, 27% ( $n = 23$ ) were s1/i2, and 11% ( $n = 9$ ) were s2/i2. Consistent with previous reports, no s2/i1-type strains were isolated from this cohort. Because carriage of s2-type strains was rare, we were unable to compare s1 and



**Figure 4.** Expression of s1/i1-type *vacA* induces more severe gastric inflammation and spasmodic polypeptide-expressing metaplasia (SPEM) in the C57BL/6J mouse SS1 *Helicobacter pylori* infection model. Groups of 5–6 mice per study were inoculated with SS1 expressing s1/i1-, s1/i2-, or s2/i2-type *VacA* in Brucella broth. After 3 weeks, the severity of inflammation and SPEM in stomach sections were quantified histologically using an adapted Sydney scoring system. Inflammation and SPEM extent were quantified by measuring the length of inflamed or metaplastic corpus and expressing each as a proportion of the total corpus length examined. Data presented are combined from 2 independent studies; in each study, all 3 groups were examined in parallel. Horizontal lines indicate median values for each group. *P* values were calculated with 2-tailed Mann–Whitney tests.

s2 effects in this study but could not directly compare i1 and i2 effects in the s1 background.

There were no differences in levels of inflammation, activity, atrophy, or colonization density between patients infected with *vacA* i1-type or i2-type strains (data not shown), but a marked difference was seen in levels of intestinal metaplasia (Figure 6). Intestinal metaplasia was detected in only 1 of 32 patients (3%) infected with an i2-type strain, with only mild severity, but mild, moderate, or severe intestinal metaplasia were seen in 15 of 53 patients (28%) infected with an i1-type strain ( $P < .01$ ; Figure 6A–C).


Because *vacA* i1-type strains also tend to be *vacA* s1 type and *cagA* positive, we first excluded *vacA* s2-type strains (Figure 6D) and then *vacA* s1-type, *cagA*<sup>−</sup> strains (Figure 6E) from our analysis. The association of intestinal metaplasia with *vacA* i1 type remained when s2-type strains were excluded (28% of patients with s1/i1 strains had intestinal metaplasia vs 4% with s1/i2 strains;  $P < .05$ ). When all *cagA*<sup>−</sup> strains were also excluded, 26% of patients (11 of 43) with i1 strains had intestinal metaplasia, compared with only 8% (1 of 13) with i2 strains. There was also a trend toward an association between the *vacA* i1 allele and intestinal metaplasia in patients infected with *vacA* s1,

*cagA*<sup>−</sup> strains ( $P = .10$ ; Figure 6F), although consistent with other reports, such strains were uncommon in our patient cohort.

## DISCUSSION

Although several studies using *vacA* null mutant strains in animal models have aimed to clarify the contribution of the *VacA* toxin to pathogenesis, findings have been mixed [23–26]. The consensus now emerging is that *VacA* does confer a colonization advantage in mice, but in humans nearly all strains are *vacA* positive, and the critical determinant of disease risk is the type of toxin expressed, rather than its presence or absence. We used strains with *VacA* types found to occur naturally in human infection but on an isogenic background to remove all other strain differences. We selected a functionally *cagPAI*-null background to remove any confounding or masking effects, because *CagA* is known to cause inflammation in animal models [21, 37].

Consistent with findings in other SS1-mouse studies, we found that our SS1<sup>s2i2</sup> strain colonized C57BL/6J mice readily. Our SS1<sup>null</sup> mutants had reduced colonization rates, consistent with the impaired colonization reported elsewhere for *vacA*-null



**Figure 5.** Inoculation of C57BL/6J mice with SS1<sup>s1i1</sup> or SS1<sup>s2i2</sup> induces progressive inflammation and spasmodic polypeptide-expressing metaplasia (SPEM). Groups of 5–10 mice were infected with SS1 expressing s2/i2 (A) or s1/i1 (B) type VacA in Brucella broth. After 1, 3, or 6 weeks, stomach sections were histologically scored using an adaptation of the Sydney system, and inflammation and SPEM extent expressed as percentage of total corpus length examined with scores of 1 (mild) to 3 (severe). The severity and extent of inflammation and SPEM increased progressively with infection time for both SS1<sup>s2i2</sup> and SS1<sup>s1i1</sup>. Horizontal lines indicate median values for each group.


SS1 [25] and PMSS1 [26]. We also found that strains producing s1/i1 and s1/i2 VacA had reduced colonization success rates and densities. This is the first evidence, to our knowledge, of a positive role for the less-active s2/i2 form of VacA compared with the s1/i2 or s1/i1 forms.

Many human studies have shown associations between strains with active forms of VacA and disease, and the best of these have controlled for other virulence factors, including *cag*-PAI status. However, doubts about the direct importance of VacA in disease have remained, in part because animal model experiments have proved difficult and the effects of VacA described in these models have largely been confined to colonization differences. By introducing isogenic hybrid forms of VacA in a mouse-colonizing *H. pylori* strain with a *cag*-null background, we have demonstrated independent effects of VacA on induction of inflammation and metaplasia, showing that the s1/i1 type of VacA is the most pathogenic, consistent with known disease associations in humans.

Mice in the studies presented in Figures 4 and 5 were from the same supplier, housed in the same facility, and treated

identically but were from multiple batches, dosed on separate occasions. Although colonization densities in infected mice were consistent within each group across 4–5 independent experiments per group (Figure 2), levels of inflammation and SPEM were quite variable. We suggest that batch variation, perhaps in non-*H. pylori* gastric flora, may contribute to the histological parameters measured. However, SS1<sup>s1i1</sup> consistently induced more severe and extensive inflammation and SPEM than SS1<sup>s2i2</sup>, despite colonizing poorly. It is possible that induction of inflammation and damage by the strains producing more active VacA contributed to the reduced colonization densities achieved by these strains. However, we did not see any significant correlation between colonization density and gastric pathology in this study.

*H. pylori* is not a natural colonizer of mice, and there are immunological and physiological differences between mice and humans. Thus, it is important to show relevance in a human population. The results in our UK population were more dramatic than we expected, given the relatively modest differences seen in mice: intestinal metaplasia was found in many patients



**Figure 6.** Carriage of *vacA* i1-type strains is associated with increased incidence of intestinal metaplasia in the human stomach. The severity of intestinal metaplasia in gastric biopsy specimens from patients infected with *vacA* s2i2- (n = 9), s1i2- (n = 23), or s1i1- (n = 53) type *Helicobacter pylori* strains was scored in a blinded fashion by a qualified histopathologist. Intestinal metaplasia was seen in a single patient infected with an i2-type strain (3%) but was present in 28% of patients infected only with i1-type strains (A–C). The association between *vacA* i type and intestinal metaplasia remained when only patients infected with *vacA* s1-type strains (D) were included, and similar trends were observed in groups infected with *vacA* s1-type, *cagA*<sup>+</sup> (E) and *vacA* s1-type, *cagA*<sup>-</sup> strains (F). Data were analyzed using a Kruskal–Wallis test with Dunn posttest (A) and Fisher exact tests (B–F).

infected with *vacA* s1/i1 strains, regardless of *cag* status, but in only 1 patient who did not have an s1/i1 strain isolated, and in that patient the findings were grade 1 only (mild). This raises several interesting issues. First, because s2/i1 strains are rarely found naturally, it might only be necessary to type the i region to identify metaplasia-associated strains. Second, it is not surprising that many s1/i1 strains were not associated with metaplasia; we regard these as metaplasia-inducing strains, but many other factors, including age, length of infection, environmental cofactors, and host genetics, are likely to determine whether an individual will develop metaplasia or will have developed it by the time of the study. Furthermore, metaplasia is a patchy phenomenon in the human stomach, and single-pinch biopsy specimens may not detect it reliably.

There are some interesting differences between our findings in mice and humans. Only in mice were there associations between *vacA* type and inflammation. This may be because *cag* is the dominant driver of inflammation in humans, and in our mice, to avoid confounding effects, we used a *cag*-null strain background. However, in humans we saw a strong association between *vacA* i1 strains and metaplasia despite seeing no difference in levels of gastric inflammation. This may imply that VacA is driving metaplasia through a different mechanism, for example, through a direct toxic effect on the gastric epithelium. However, there are alternative explanations; for example, there may have been different levels of inflammation earlier in life, even in childhood, that are no longer evident in long-established infection. A second interesting difference is that



even quite severe metaplasia was sometimes found in mice infected with *vacA* s2/i2 or s1/i2 strains. In humans, only s1/i1 strains were associated with moderate or severe metaplasia.

Human and mouse *H. pylori* infections are very different, and it would be surprising if the same level of disease was observed in both. However, because non-i1 strains can cause metaplasia in mice, it is important to study the association of such strains with metaplasia in humans in larger and different populations. This may be clinically important: if *vacA* i2 strains are rarely associated with metaplasia and cancer in human populations, there is no need to treat them to prevent cancer.

## Notes

**Acknowledgments.** Thanks to the staff at the Biomedical Services Unit, University of Nottingham, for technical assistance with mouse infection studies and animal husbandry, and thanks to the patients and staff at Nottingham University Hospital.

**Contributors.** K. R. and J. C. A. conceived and planned the study. J. A. W., D. P. L., K. W. C., J. L. R., A. A. M. Z., R. J. M. I., K. R. A., N. J. C., P. V. K. and K. R. carried out the experimental work. J. A. W., D. P. L., K. R. and J. C. A. analyzed the data. J. A. W., D. P. L., K. R. and J. C. A. wrote the manuscript.

**Financial support.** This work was supported by Cancer Research UK (grant C8968/A11204) and the National Institute for Health Research (NIHR), through the NIHR Biomedical Research Unit in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust and the University of Nottingham. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health. The study design, collection, analysis and interpretation of data, writing of the report, and decision to submit for publication were undertaken independently by the authors without involvement of the funders. R. J. M. I. was supported by a Clinical Research Training Fellowship (G1000311) from the Medical Research Council.

**Potential conflicts of interest.** All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

## References

- Kuipers EJ, Thijs JC, Festen HP. The prevalence of *Helicobacter pylori* in peptic ulcer disease. *Aliment Pharmacol Ther* **1995**; 9(Suppl 2):59–69.
- Ernst PB, Gold BD. The disease spectrum of *Helicobacter pylori*: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. *Ann Rev Microbiol* **2000**; 54:615–40.
- El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* **2000**; 404:398–402.
- Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, *Helicobacter pylori*, and smoking. *J Clin Gastroenterol* **1997**; 24:2–17.
- Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of *Helicobacter pylori* infection. *Clin Microbiol Rev* **2006**; 19:449–90.
- Cover TL, Blaser MJ. Purification and characterization of the vacuolating toxin from *Helicobacter pylori*. *J Biol Chem* **1992**; 267:10570–5.
- Cover TL, Krishna US, Israel DA, Peek RM Jr. Induction of gastric epithelial cell apoptosis by *Helicobacter pylori* vacuolating cytotoxin. *Cancer Res* **2003**; 63:951–7.
- Gebert B, Fischer W, Weiss E, Hoffmann R, Haas R. *Helicobacter pylori* vacuolating cytotoxin inhibits T lymphocyte activation. *Science* **2003**; 301:1099–102.
- Noto JM, Peek RM Jr. The *Helicobacter pylori* *cag* pathogenicity island. *Methods Mol Biol* **2012**; 921:41–50.
- Letley DP, Rhead JL, Twells RJ, Dove B, Atherton JC. Determinants of non-toxicity in the gastric pathogen *Helicobacter pylori*. *J Biol Chem* **2003**; 278:26734–41.
- Rhead JL, Letley DP, Mohammadi M, et al. A new *Helicobacter pylori* vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. *Gastroenterology* **2007**; 133:926–36.
- McClain MS, Cao P, Iwamoto H, et al. A 12-amino-acid segment, present in type s2 but not type s1 *Helicobacter pylori* VacA proteins, abolishes cytotoxin activity and alters membrane channel formation. *J Bacteriol* **2001**; 183:6499–508.
- Ji X, Fernandez T, Burrone D, et al. Cell specificity of *Helicobacter pylori* cytotoxin is determined by a short region in the polymorphic midregion. *Infect Immun* **2000**; 68:3754–7.
- Atherton JC. The pathogenesis of *Helicobacter pylori*-induced gastroduodenal diseases. *Ann Rev Pathol* **2006**; 1:63–96.
- Yordanov D, Boyanova L, Markovska R, Gergova G, Mitov I. Significance of *Helicobacter pylori* *vacA* intermediate region genotyping—a Bulgarian study. *Diagn Microbiol Infect Dis* **2012**; 74:253–7.
- Ferreira RM, Figueiredo C, Bonet C, et al. *Helicobacter pylori* *vacA* intermediate region genotyping and progression of gastric preneoplastic lesions. *Am J Gastroenterol* **2012**; 107:145–6.
- Basso D, Zambon CF, Letley DP, et al. Clinical relevance of *Helicobacter pylori* *cagA* and *vacA* gene polymorphisms. *Gastroenterology* **2008**; 135:91–9.
- Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, Dixon MF. A standardized mouse model of *Helicobacter pylori* infection: introducing the Sydney strain. *Gastroenterology* **1997**; 112:1386–97.
- Barrozo RM, Cooke CL, Hansen LM, et al. Functional plasticity in the type IV secretion system of *Helicobacter pylori*. *PLoS Pathog* **2013**; 9:e1003189.
- Philpott DJ, Belaid D, Troubadour P, et al. Reduced activation of inflammatory responses in host cells by mouse-adapted *Helicobacter pylori* isolates. *Cell Microbiol* **2002**; 4:285–96.
- Arnold IC, Lee JY, Amieva MR, et al. Tolerance rather than immunity protects from *Helicobacter pylori*-induced gastric preneoplasia. *Gastroenterology* **2011**; 140:199–209.
- Algood HM, Torres VJ, Unutmaz D, Cover TL. Resistance of primary murine CD4+ T cells to *Helicobacter pylori* vacuolating cytotoxin. *Infect Immun* **2007**; 75:334–41.
- Eaton KA, Cover TL, Tummuru MK, Blaser MJ, Krakowka S. Role of vacuolating cytotoxin in gastritis due to *Helicobacter pylori* in gnotobiotic piglets. *Infect Immun* **1997**; 65:3462–4.
- Wirth HP, Beins MH, Yang M, Tham KT, Blaser MJ. Experimental infection of Mongolian gerbils with wild-type and mutant *Helicobacter pylori* strains. *Infect Immun* **1998**; 66:4856–66.
- Salama NR, Otto G, Tompkins L, Falkow S. Vacuolating cytotoxin of *Helicobacter pylori* plays a role during colonization in a mouse model of infection. *Infect Immun* **2001**; 69:730–6.
- Oertli M, Noben M, Engler DB, et al. *Helicobacter pylori* gamma-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. *PNAS (USA)* **2013**; 110:3047–52.
- Cover TL, Tummuru MK, Cao P, Thompson SA, Blaser MJ. Divergence of genetic sequences for the vacuolating cytotoxin among *Helicobacter pylori* strains. *J Biol Chem* **1994**; 269:10566–73.
- Miles AA, Misra SS, Irwin JO. The estimation of the bactericidal power of the blood. *J Hyg* **1938**; 38:732–49.
- Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis: the updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol* **1996**; 20:1161–81.
- Atherton JC, Cao P, Peek RM Jr, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*: association of specific *vacA* types with cytotoxin production and peptic ulceration. *J Biol Chem* **1995**; 270:17771–7.
- Atherton JC, Cover TL, Twells RJ, Morales MR, Hawkey CJ, Blaser MJ. Simple and accurate PCR-based system for typing vacuolating cytotoxin alleles of *Helicobacter pylori*. *J Clin Microbiol* **1999**; 37:2979–82.

32. Argent RH, Thomas RJ, Aviles-Jimenez F, et al. Toxigenic *Helicobacter pylori* infection precedes gastric hypochlorhydria in cancer relatives, and *H. pylori* virulence evolves in these families. *Clin Cancer Res* **2008**; *14*:2227–35.
33. van Doorn NE, Namavar F, Sparrius M, et al. *Helicobacter pylori*-associated gastritis in mice is host and strain specific. *Infect Immun* **1999**; *67*:3040–6.
34. Crabtree JE, Ferrero RL, Kusters JG. The mouse colonizing *Helicobacter pylori* strain SS1 may lack a functional *cag* pathogenicity island. *Helicobacter* **2002**; *7*:139–40; author reply 40–1.
35. Kawazoe T, Sakagami T, Nakajima K, et al. Role of bacterial strain diversity of *Helicobacter pylori* in gastric carcinogenesis induced by N-methyl-N-nitrosourea in Mongolian gerbils. *Helicobacter* **2007**; *12*:213–23.
36. Syu LJ, El-Zaatari M, Eaton KA, et al. Transgenic expression of interferon-gamma in mouse stomach leads to inflammation, metaplasia, and dysplasia. *Am J Pathol* **2012**; *181*:2114–25.
37. Wiedemann T, Loell E, Mueller S, et al. *Helicobacter pylori cag*-pathogenicity island-dependent early immunological response triggers later precancerous gastric changes in Mongolian gerbils. *PloS One* **2009**; *4*:e4754.